Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment
ConclusionsTaken together, our observations indicate that regorafenib is beneficial in the treatment of patients with advanced HCC who progressed on or demonstrated intolerance to sorafenib therapy; however, careful selection and close monitoring of patients is necessary to maximize the benefit while minimizing the toxicities of regorafenib treatment.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Children | Clinical Trials | Drugs & Pharmacology | Hepatocellular Carcinoma | Laboratory Medicine | Lithium | Liver | Liver Cancer | Liver Transplant | Skin | Toxicology | Transplant Surgery | Transplants | Urology & Nephrology